Showing 1–25 of 59 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Olanisun P Adewole, MD, Bolanle A Omotoso, MD
Tuberculosis (TB) is caused by mycobacterial organism. It is the leading infectious disease cause of death globally, with more than 10 million new cases and over 2 million deaths annually. Developing countries bear the greatest brunt of the disease. The long duration of current t…
Álvaro H Borges, Marisa Russell, Dereck Tait, Thomas J Scriba, Elisa Nemes, et al.
**BACKGROUND:** People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown. **METHODS:** In…
First Affiliated Hospital of Zhejiang University
…and moxifloxacin for ethambutol) for treatment of pulmonary tuberculosis. The standard six-month regimen is two months of isoniazid, rifampin, ethambutol, and pyrazinamide, followed by four months of isoniazid and rifampin. The four-month regimen consists of two months of isoniaz…
Susan Dorman, MD, Payam Nahid, MD, MPH, Susan Swindells, MBBS, Richard Chaisson, MD, Ekaterina V Kurbatova, MD, PhD, MPH
…y is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week, with direct observation of each dose …
Shanghai Pulmonary Hospital, Shanghai, China
…loxacin, and pyrazinamide in patients with drug-susceptible tuberculosis. This is a prospective, randomized, controlled, multicenter study planned to enroll 45 rifampicin-susceptible tuberculosis patients, who will be randomized in a 1:1:1 ratio to the BZMD group (bedaquiline + p…
Rada Savic, PhD
The Tuberculosis Trials Consortium (TBTC) phase 3 treatment trial, Study 31, will investigate the efficacy and safety of daily rifapentine (1200 mg daily) with or without moxifloxacin as part of multidrug treatment regimens for drug-sensitive pulmonary TB. The proposed study (Stu…
Daniel W Fitzgerald, MD, Carl Nathan, MD, Jean William Pape, MD
…(NTZ) will cause a significant decrease in the number of M. tuberculosis bacteria in sputum after 14 days of treatment. The study is being conducted at the GHESKIO Centers in Port au Prince Haiti This is a prospective randomized two-arm 14-day, early bactericidal activity study …
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis (TB) is a serious infection that can affect the lungs and other parts of the body. The usual way to treat TB is to take 4 medicines by mouth every day for 2 months, then take 2 of the same medicines for 4 more months, for a total of 6 months. The purpose of this stud…
Heiman F Wertheim, PhD
Detection of M. tuberculosis in clinical specimens of children has a low sensitivity because specimens are either difficult to collect or contain low levels of M. tuberculosis. Diagnostic criteria are non-specific and culture confirmation is challenging, as sputum samples are not…
Benjamin WYPLOSZ, Ph
… viability test in large cohort of smear-positive pulmonary tuberculosis patients under treatment and to determine if the test could help physicians to discontinue isolation measures in hospital setting. When patients with pulmonary tuberculosis (TB) are hospitalized for diagnos…
John Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, Alberto Mendoza-Ticona, Samuel Pierre, et al.
…ed with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine load…
Bart G J Dekkers, Huib A M Kerstjens, Helene W Breisnes, Diana J Leeming, Richard M Anthony, et al.
… reduce excessive inflammation and prevent tissue damage in tuberculosis are being investigated. Macrolides, including azithromycin, were shown to possess anti-inflammatory and immune-modulatory effects in addition to their antibacterial effects. In the current trial, we investig…
Muhammad Shahzad
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a deadly infectious disease and major global public health problem. Recent evidence from animal studies suggests that the microbiome plays a role in TB pathogenesis and immune response. However, until now, no simil…
Ekaterina V Kurbatova, Kelly E Dooley, Wendy Carr, Jason E Stout, Eric L Nuermberger, et al.
…t shorten treatment duration for drug-susceptible pulmonary tuberculosis. **METHODS/DESIGN:** We describe the design of Tuberculosis Trials Consortium (TBTC) Study 38/CRUSH-TB (NCT05766267), an open-label multicenter international randomized controlled phase 2C trial that compar…
Grant Theron, PHD
… of the 1.7 billion individuals infected with Mycobacterium tuberculosis (Mtb) will progress to active tuberculosis (TB). This probability increases in people with human immunodeficiency virus (HIV) and other risk co-morbidities such as malnutrition, diabetes and substance abuse.…
Susan Shin-Jung Lee, MD, PhD
Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030. With the concerted efforts of the government and medical community, the incidence of TB in Taiwan has gradually decreased, however, Taiwan remains an e…
Beijing Chest Hospital
… shorter-course BLMZ regimen can treat Rifampicin-Resistant Tuberculosis (RR-TB) in Chinese participants aged 12 years and older. The main questions it aims to answer are: What is the proportion of participants with a favorable outcome at 18 months after starting the BLMZ regime…
M Olugbosi, M Beumont, L Lombard, J Nedelman, J Timm, et al.
**INTRODUCTION:** In 2023, tuberculosis (TB) returned to being the world's leading cause of death from a single infectious agent. Current standard of care for drug-sensitive tuberculosis (DS-TB) treatment has a long duration with risk of poor compliance and outcomes and increased…
Hamu J Mlyuka, Alphonce Liyoyo, Belinda Nyaulingo, Emmanuel Mpolya, Oscar L Kaswaga, et al.
…rrent combination antibiotic treatment for drug-susceptible tuberculosis (DS-TB) usually takes 6 months to complete. This long duration can compromise clinical outcomes. Although a 4-month regimen including an optimized dose of rifapentine plus moxifloxacin is non-inferior to sta…
John Metcalfe, MD, PhD, MPH
…th standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB). This study compared a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB). Rando…
Radojka Savic, PharmD, PhD, Kelly Dooley, MD, PhD, Gustavo Velásquez, MD, MPH
…for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liqui…
Linda prof
…nosed, bacteriologically confirmed drug-sensitive pulmonary tuberculosis. The main questions it aims to answers are: * Does adjunct n-3 LCPUFA supplementation reduce the sputum culture time to positivity * Does it improve inflammatory markers and TB treatment outcomes compared …
Katarina Niward, MD, PhD
Tuberculosis (TB) treatment is long and complex with the risk of poor treatment adherence and treatment failure. Several attempts to shorten treatment of drug-susceptible TB have been unsuccessful. However, recent data support a shortened regimen for mild and moderate pulmonary T…
Sohag University
Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is fundamental. Identifying the pattern of drug resista…
Lina Davies Forsman, MD, PhD
…estions: In adult patients with drug-susceptible pulmonary tuberculosis, can current dose recommendations and information received from MIPD help clinicians in a timely manner to optimise the drug exposure of TB drugs in the early treatment phase, i.e., the time from PK sampling…